IRIS
TORRE, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.796
AS - Asia 12
SA - Sud America 5
Totale 4.813
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 4.796
CN - Cina 8
VN - Vietnam 4
AR - Argentina 2
BR - Brasile 2
PY - Paraguay 1
Totale 4.813
Salva come PNG Salva come JPEG
Città #
Genova 3.013
Genoa 1.070
Rapallo 438
Vado Ligure 270
Bordighera 5
Beijing 3
Bắc Ninh 1
Campinas 1
Da Nang 1
Encarnación 1
La Rioja 1
Lấp Vò 1
Nossa Senhora da Glória 1
Quảng Ngãi 1
Resistencia 1
Totale 4.808
Salva come PNG Salva come JPEG
Nome #
Hepatitis G virus infection in haemodialysis and in peritoneal dialysis patients. 200
A new assay for hepatitis C virus (HCV) core antigen detection: an alternative to nucleic acid technologies in positive or indeterminate anti-HCV subjects? 196
Atherosclerosis in Rheumatoid Arthritis: Promoters and Opponents 195
Peripheral blood serum markers for apoptosis and liver fibrosis: Are they trustworthy indicators of liver realness? 159
Circadian secretion of melatonin and thyrotropin in hospitalized aged patients. 156
Direct evidence that naturally occurring mutations within hepatitis B core epitope alter CD4+ T-cell reactivity. 151
Soluble apoptosis molecules in primary biliary cirrhosis: analysis and commitment of the Fas and tumour necrosis factor-related apoptosis-inducing ligand systems in comparison with chronic hepatitis C. 143
Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. 143
Clinical implications of mutations in the hepatitis B virus genome. 139
Antiviral activity of amantadine in elderly patients with chronic hepatitis C 135
Clearance kinetics of hepatitis C virus under different antiviral therapies. 134
Clinical and virological survey of patients with hepatitis B surface antigen in an Italian region: clinical considerations and disease burden 128
Effects of pyridostigmine, corticotropin-releasing hormone and growth hormone-releasing hormone on the pituitary-adrenal axis and on growth hormone secretion in dementia. 128
Interferon retreatment in chronic hepatitis C: wich patients to choose, and what schedule to use 125
Monotherapy with Pegylated Interferon Alpha-2a in Hemodialyzed Patients with Chronic Hepatitis C 125
Pegylated interferon and ribavirin in re-treatment of responder-relapser HCV patients. 124
Evolution of wild-type and precore mutant HBV infection after liver transplantation. 118
Continuous lamivudine treatment in an OLT patient despite the appearance of HBV resistant strain: longitudinal analysis. 117
Regression of Fibrosis After DAAs Treatment of Patients with HCV Cirrhosis: Transposability to Non-Decompensated Patients 116
TT virus infection in haemodialysis patients 113
Serum lamivudine levels in the presence of a lamivudine-resistant HBV mutant 112
Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection. 112
Soluble tumor necrosis factor-related ligand (sTRAIL) levels and kinetics during antiviral treatment in chronic hepatitis C 112
Prospective evaluation of primary infection due to HCV, HGV or TTV in children with newly diagnosed neoplasia. 111
A significant proportion of patients with chronic hepatitis B who are candidates for antiviral treatment are untreated: a region-wide survey in Italy 110
Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals 110
Kinetics of soluble tumour necrosis factor (TNF)-alpha receptors and cytokines in the early phase of treatment for chronic hepatitis C: comparison between interferon (IFN)-alpha alone, IFN-alpha plus amantadine or plus ribavirin. 109
Elevations in ALT levels late the course of antiviral therapy in HCV-RNA negative patients are associated with virological relapse 108
Chronic hepatitis C. New therapeutic strategies. 106
Amantadine: a different approach. 103
Hepatitis B virus variants with core gene deletions in the evolution of chronic hepatitis B infection. 103
Novel immunoassay for the detection of hepatitis B surface 'escape' mutants and its application in liver transplant recipients. 102
Interferon beta-1a alone or in combination with ribavirin: a randomized trial to compare efficacy and safety in chronic hepatitis C. 100
Course of oesophageal varices and performance of non-invasive predictors following Hepatitis C Virus clearance in compensated advanced chronic liver disease 100
Induction of T-helper cell response to hepatitis B core antigen in chronic hepatitis B: a major factor in activation of the host immune response to the hepatitis B virus. 95
Initial high dose of lamivudine delays the appearance of viral resistance in chronic hepatitis B patients 90
Evaluation of a new hepatitis C virus sequecing assay as a routine method for genotyping 84
Sex hormones, gonadotropins and prolactin in male epileptic subjects in remission: role of the epileptic syndrome and of antiepileptic drugs. 82
Erythrocytes cell wall defects correlate with the stage of liver cirrhosis 75
Soluble beta2-mu-associated and beta2-mu-free HLA class I heavy chain serum levels in interferon-alpha nonresponder chronic hepatitis C patients. Markers of immune activation, and response to antiviral retreatment. 65
Totale 4.834
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.162
article - articoli 14.162
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.324
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021215 0 0 0 31 29 22 11 29 23 31 21 18
2021/2022453 13 26 27 46 17 42 31 112 21 56 14 48
2022/2023536 59 58 7 45 81 90 3 48 86 5 48 6
2023/2024224 7 37 3 31 22 34 5 8 13 1 28 35
2024/2025729 30 43 11 54 96 57 59 150 17 26 80 106
2025/2026313 177 30 44 62 0 0 0 0 0 0 0 0
Totale 4.834